Compounds that bind HER2

Details Compounds that bind HER2 Compounds that bind HER2

2006-01-17

2006-01-17

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S387300, C435S069100, C435S320100, C435S252300, C435S325000, C435S006120, C514S012200

Reexamination Certificate

active

06987088

ABSTRACT:
The invention provides novel compounds which bind to the human erbB2 gene product (ErbB2, also known as HER2, or c-ErbB-2). In particular aspects, the invention provides for the treatment of disorders characterized by the overexpression of ErbB2 utilizing the novel compounds of the invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as for their use in research, diagnostic, therapeutic, and prophylactic methods.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5279966 (1994-01-01), Jessell et al.
patent: 5578482 (1996-11-01), Lippman et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5869618 (1999-02-01), Lippman et al.
patent: 5871969 (1999-02-01), Hastings et al.
patent: 6414130 (2002-07-01), Doherty et al.
patent: WO 98/17797 (1998-04-01), None
patent: WO 98/57989 (1998-12-01), None
patent: WO 99/14323 (1999-03-01), None
patent: WO 99/31140 (1999-06-01), None
patent: WO 99/39729 (1999-08-01), None
patent: WO 00/24782 (2000-05-01), None
patent: WO 01/61356 (2001-08-01), None
Seq IG No.:15 (sequence search results only).
Seq IG No.:8 (sequence search results only).
Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model”Science279:377-380 (1998).
Baselga et al., “Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2Monoclonal Antibody in Patients With HER2
eu-Overexpressing Metastatic Breast Cancer”J. Clin. Oncol.14(3):737-744 (Mar. 1996).
Clackson and Wells, “In vitro selection from protein and peptide libraries”Trends Biotechnol.12:173-184 (1994).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor—Factor VIIa; I. Potent Inhibitors Selected from Libraries by Phage Display”Journal of Biological Chemistry269(35):22129-22136 (1994).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor—Factor VIIa; II. Potent and Specific Inhibitors by Competitive Phage Selection”Journal of Biological Chemistry269(35):22137-22144 (1994).
Hudziak et al., “Cell transformation potential of a HER2 transmembrane domain deletion mutant retained in the endoplasmic reticulum”Journal of Biological Chemistry266:24109-24115 (1991).
Jones et al., “Binding specificities and affinities of egf domains for ErbB receptors”FEBS Letters447:227-231 (1999).
Lowman and Wells, “Affinity Maturation of Human Growth Hormone by Monovalent Phage Display”J. Mol. Biol.234:564-578 (1993).
Lowman et al., “Molecular Mimics of Insulin-Like Growth Factor 1 (IGF-1) for Inhibiting IGF-1: IGF-Binding Protein Interactions.”Biochemistry37(25):8870-8878 (1998).
Lowman et al., “Selecting High-Affinity Binding Proteins by Monovalent Phage Display”Biochemistry30(45):10832-10838 (1991).
Lowman, H., “Bacteriophage display and discovery of peptide leads for drug development”Annual Review of Biophysics and Biomolecular Structure26:401-424 (1997).
Lowman, H., “Phage display of peptide libraries on protein scaffolds”Methods in Molecular Biology,Chapter 24, 87:249-264 (1998).
Pasqualini and Ruoslahti, “Organ targeting in vivo using phage display peptide libraries”Nature380:364-366 (1996).
Seelig et al., “Synthetic mimics of juxtaposed amino- and carboxyl-terminal peptide domains of human γ interferon block ligand binding to human γ interferon receptor”Chemical Abstracts(abstract #75131) 120(7):678 (1994).
Seelig et al., “Synthetic Mimics of Juxtaposed Amino- and Carboxyl-terminal Peptide Domains of Human γ Interferon Block Ligand Binding to Human γ Interferon Receptor”Journal of Biological Chemistry269(1):358-363 (1994).
Semba et al., “A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma”Proc. Natl. Acad. Sci. USA82:6497-6501 (1985).
Wells and Lowman, “Rapid Evolution of Peptide and Protein Binding Properties in Vitro”Curr. Opin. Struct. Bio.2:597-604 (1992).
Yamamoto et al., “Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor”Nature319:230-234 (1986).

Affiliated with

Also associated with

Rating

Compounds that bind HER2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds that bind HER2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds that bind HER2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3554376